Affibody molecules are small (6.5-kDa) affinity proteins based on a three-helix bundle
domain framework. Since their introduction 20 years ago as an alternative to antibodies for …

Abstract Development of peptide drugs is challenging but also quite rewarding. Five
blockbuster peptide drugs are currently on the market, and six new peptides received first …

Clinical applications of recombinant human tumor necrosis factor-related apoptosis-inducing
ligand (hTRAIL) have been limited by their poor pharmacokinetics. Using endogenous …

The pharmaceutical market has largely been dominated by small molecule drugs; however,
larger biomolecules have recently become important contenders. Of these biomolecules …

One of the major design considerations for a drug is its pharmacokinetics: a drug with short
blood half-life is less available at a target organ which in turn dictates treatment with either …

The prevalence of obesity along with its related metabolic diseases has increased globally
in recent decades. Obesity originates from a heterogeneous physiological state, which is …

Genetic fusion of a therapeutic protein to albumin can improve its stability and
pharmacokinetics, but it usually leads to considerably reduced bioactivity and poor tumor …

Although the peptide, exenatide, has been widely used as a drug for the treatment of type 2
diabetes, its short plasma half-life requires frequent subcutaneous injection, resulting in poor …

Radiolabeled Affibody-based targeting agent 177Lu-ABY-027, a fusion of an anti-HER2
Affibody molecule with albumin binding domain (ABD) site-specifically labeled at the C …

Targeting the gastrin-releasing peptide receptor (GRPR) with the bombesin analogue
RM26, a 9 aa peptide, has been a promising strategy for cancer theranostics, with recent …